Clinical Trial Details


Research Study Summary

An 8-week, randomzied, double-blind, placebo-controlled, parallel-group, multi-center study of the efficacy and safety of agomelatine 0.5mg and 1mg sublingual tablets administered once daily in patients with Major Depressive Disorder (MDD).


The purpose of this study is to find out if two different doses of agomelatine are safe and tolerable, and can help people who have major depressive disorder. The study doctor will also give agomelatine to some people in this study to find out if taking agomelatine is better than taking placebo. Placebo is a tablet that looks like an active drug but has no drug or other active ingredient

Please contact Alexian Brothers for more information on participation.

To Learn more

CW ID: 176873
Date Last Changed: July 22, 2013

Clinical Trial Snapshot

Both Male and Female
Overall Status
8 Weeks
Facility Type


Alexian Brothers Hospital Network
1786 Moon Lake Boulevard, Suite 200
Hoffman Estates, IL 60169
Phone: 847-230-3599

View Map

Research Center Information:

Alexian Brothers Hospital Network

Volunteer for this Trial

If you would like to learn more about participating in this research study, please email the trial contact using the form below. We value your privacy and your information will only be used by the research center to contact you regarding this study.

DISCLAIMER: CenterWatch does not conduct clinical research. CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies, contract research organizations, clinical research sites and other interested parties. This information is designed to help patients find clinical trials of interest and contact the research centers conducting the trials.